Circadian molecular regulation of the xenobiotic response
Circadian molecular regulation of the xenobiotic response
批准号:
8527278
负责人:
Katja A Lamia
金额:
$41.22万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-04-01 至 2018-03-31
关键词:
5&apos-AMP-activated protein kinaseAgonistAntidiabetic DrugsAntihypertensive AgentsAutomobile DrivingBehaviorBiochemicalBiochemical GeneticsBiological AssayBlood PressureCYP3A4 geneCellsChargeChromatinCircadian RhythmsDependenceDevelopmentDiabetes MellitusDiseaseDrug PrescriptionsDrug TransportDrug toxicityEnzymesGenesGenetic TranscriptionGlucocorticoid ReceptorGlucoseHepaticHepatocyteHumanLeadLigandsLiverMarketingMeasuresMediatingMetabolic DiseasesMetabolic syndromeMetabolismMetforminMolecularMusNon-Insulin-Dependent Diabetes MellitusNuclear Hormone ReceptorsNutrientPOU2F1 genePathway interactionsPharmaceutical PreparationsPhosphorylationPhysiologicalPhysiological ProcessesPhysiologyPredispositionProtein IsoformsPublic HealthRegulationRelative (related person)RepressionRoleSpecificityTertiary Protein StructureTherapeuticTimeToxic effectTranscriptTranscriptional RegulationTreatment EfficacyUnited StatesXenobiotic MetabolismXenobioticsabsorptionatorvastatinbaseblood glucose regulationcircadian pacemakercryptochromedrug metabolismglucophagein vivoinsightknowledge basenovelnovel therapeuticspreferencepregnane X receptorpublic health relevancereceptorresponsesmall moleculetooluptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Circadian clocks have recently become recognized as modulators of a wide array of physiological processes, including glucose homeostasis, blood pressure modulation, and drug metabolism and toxicity. Several drugs, including the anti-hypertensive statins (e.g. Lipitor) and the anti-diabetic drug metformin (e.g. Glucophage), are recommended to be taken at specific times of day. However, the molecular basis for these preferences is not well understood. The underlying hypothesis of this proposal is that the cellular transport and metabolism of therapeutic drugs can be modulated at the transcriptional level by circadian repressors altering the function of nuclear hormone receptors that respond to xenobiotic ligands. Advancing our functional understanding of these receptor and repressor interactions may highlight new therapeutic strategies for treating disease. For example, defining the diurnal regulation of the xenobiotic transcriptional network could enable the prediction of optimal treatment times for existing and novel therapeutic compounds. In addition, a deeper understanding of the diurnal regulation of nuclear hormone receptor pathways that modulate the xenobiotic transcriptional response may lead to new strategies for modulating drug absorption, metabolism and/or toxicities. Our previous studies identified the circadian clock component cryptochromes (Cry1 and Cry2) as nutrient- responsive transcriptional regulators by virtue of their susceptibility to phosphorylation by AMP-activated protein kinase (AMPK) and their ability to modulate glucocorticoid receptor dependent transcription. We have also established an important role for the liver circadian clock in glucose homeostasis, via driving diurnal expression
of hepatic enzymes and transporters, including AMPK. In the course of those studies, we have generated unique tools and expertise that enables us to use biochemical, genetic, molecular and physiological approaches to uncover the roles of circadian clocks and of the circadian repressors Cry1 and Cry2 specifically in nuclear hormone receptor pathways governing the control of drug transport and metabolism, in the following specific aims: 1) Characterize the interactions of Cry1 and Cry2 with the xenobiotic receptors PXR and CAR (define the species and isoform specificity and ligand dependence of cryptochrome-xenobiotic receptor interactions; identify domains and sequences required for interaction), 2) Define the role of Cry1 and Cry2 in the regulation of PXR/CAR-mediated xenobiotic metabolism (identify specific transcriptional targets of PXR and CAR that are regulated by cryptochromes, measure changes in drug transport and metabolizing activities upon cryptochrome depletion), 3) Examine the roles of circadian clocks, PXR and CAR in the efficacy of metformin treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The SRBR 2022 Meeting: Rhythms of Life - from Molecules to Policy
-
批准号:10467738
-
项目类别:
-
资助金额:$2.8万
-
财政年份:2022
-
负责人:Katja A Lamia
-
依托单位:
CIRCADIAN REGULATION OF HIF2alpha IN RENAL CELL CARCINOMA
-
批准号:10613272
-
项目类别:
-
资助金额:$10.05万
-
财政年份:2022
-
负责人:Katja A Lamia
-
依托单位:
Establishing a mechanistic basis for enhanced tumorigenesis under chronic circadian disruption
-
批准号:10608913
-
项目类别:
-
资助金额:$64.01万
-
财政年份:2022
-
负责人:Katja A Lamia
-
依托单位:
Impacting Cell Growth through altered circadian proteolysis
-
批准号:9982673
-
项目类别:
-
资助金额:$44.26万
-
财政年份:2017
-
负责人:Katja A Lamia
-
依托单位:
Impacting Cell Growth through altered circadian proteolysis
-
批准号:9380870
-
项目类别:
-
资助金额:$44.26万
-
财政年份:2017
-
负责人:Katja A Lamia
-
依托单位:
Impacting Cell Growth through altered circadian proteolysis
-
批准号:10367294
-
项目类别:
-
资助金额:$0.29万
-
财政年份:2017
-
负责人:Katja A Lamia
-
依托单位:
Impacting Cell Growth through altered circadian proteolysis
-
批准号:10226276
-
项目类别:
-
资助金额:$44.26万
-
财政年份:2017
-
负责人:Katja A Lamia
-
依托单位:
Regulation of exercise physiology by mammalian cryptochromes
-
批准号:10064627
-
项目类别:
-
资助金额:$41.67万
-
财政年份:2017
-
负责人:Katja A Lamia
-
依托单位:
Circadian molecular regulation of the xenobiotic response
-
批准号:8629737
-
项目类别:
-
资助金额:$41.22万
-
财政年份:2013
-
负责人:Katja A Lamia
-
依托单位:
Circadian molecular regulation of the xenobiotic response
-
批准号:9244020
-
项目类别:
-
资助金额:$41.87万
-
财政年份:2013
-
负责人:Katja A Lamia
-
依托单位:
Circadian molecular regulation of the xenobiotic response
-
批准号:9016537
-
项目类别:
-
资助金额:$41.87万
-
财政年份:2013
-
负责人:Katja A Lamia
-
依托单位:
Circadian Repressors Cry1 and Cry2 Modulate Nuclear Hormone Receptor Function
-
批准号:8215772
-
项目类别:
-
资助金额:$14.85万
-
财政年份:2011
-
负责人:Katja A Lamia
-
依托单位:
Circadian Repressors Cry1 and Cry2 Modulate Nuclear Hormone Receptor Function
-
批准号:8420521
-
项目类别:
-
资助金额:$14.85万
-
财政年份:2011
-
负责人:Katja A Lamia
-
依托单位:
Circadian Repressors Cry1 and Cry2 Modulate Nuclear Hormone Receptor Function
-
批准号:8029477
-
项目类别:
-
资助金额:$14.85万
-
财政年份:2011
-
负责人:Katja A Lamia
-
依托单位:
海外基金